Sagimet Biosciences Inc. Series A

XNASHealth care

Last traded price · USD

$9.85

−1.01%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:25 IST · A quote does not mean the product is available to trade on your account.

Day's open: $10.25
Previous close: $9.95
Volume: 756,445
Day's high: $10.43
Day's low: $9.64

In brief

Sagimet Biosciences Inc. is a health care company listed on Nasdaq, valued at about $698M.
Its shares closed at $9.99 on 4 Nov 2026, up 31.3% over the past year.
From India you can buy SGMT in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Sagimet Biosciences Inc. (SGMT) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole SGMT share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade SGMT options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

8.2 days to cover short interest
11.5M shares were sold short at the 15 Oct 2026 settlement, 18.7% of the 61.6M shares outstanding; covering them would take 8.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Ahead of SPY, in line with its sector fund XLV over 1 year
1 month: +14.0% (SPY −1.6%, XLV +13.5%). 3 months: +15.6% (SPY −0.4%, XLV +15.5%). 1 year: +31.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: SGMT, SPY and XLV · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $9.99 was 0.8% above its 50-day average ($9.91) and 32.3% above its 200-day average ($7.55). It has closed above the 200-day for 97 sessions, since 18 Jun 2026. The 50-day average crossed above the 200-day on 4 Jun 2026, 106 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
79% of the way up its 52-week range
Closed at $9.99 on 4 Nov 2026: 12.7% below the 52-week high of $11.45 (10 Sep 2026) and 122.0% above the low of $4.50 (30 Mar 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+14.0%

6 months+19.2%

1 year+31.3%

5 years—

Newswire

About

Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.

Website

Notable moves

April 27, 2026
+38.57%
June 12, 2025
+39.10%
January 22, 2024
+170.09%

Newswire

About

Website

Notable moves

April 27, 2026
+38.57%
June 12, 2025
+39.10%
January 22, 2024
+170.09%

Sagimet Biosciences Inc. Series A

XNASHealth care

Last traded price · USD

$9.85

−1.01%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:25 IST · A quote does not mean the product is available to trade on your account.

Day's open: $10.25
Previous close: $9.95
Volume: 756,445
Day's high: $10.43
Day's low: $9.64

In brief

Sagimet Biosciences Inc. is a health care company listed on Nasdaq, valued at about $698M.
Its shares closed at $9.99 on 4 Nov 2026, up 31.3% over the past year.
From India you can buy SGMT in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Sagimet Biosciences Inc. (SGMT) shares from India?

Do I need the price of a whole SGMT share to invest?

How much can I invest in US stocks in a year?

Can I trade SGMT options or futures?

Insights

Quotes run fifteen minutes behind.

8.2 days to cover short interest
11.5M shares were sold short at the 15 Oct 2026 settlement, 18.7% of the 61.6M shares outstanding; covering them would take 8.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Ahead of SPY, in line with its sector fund XLV over 1 year
1 month: +14.0% (SPY −1.6%, XLV +13.5%). 3 months: +15.6% (SPY −0.4%, XLV +15.5%). 1 year: +31.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: SGMT, SPY and XLV · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $9.99 was 0.8% above its 50-day average ($9.91) and 32.3% above its 200-day average ($7.55). It has closed above the 200-day for 97 sessions, since 18 Jun 2026. The 50-day average crossed above the 200-day on 4 Jun 2026, 106 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
79% of the way up its 52-week range
Closed at $9.99 on 4 Nov 2026: 12.7% below the 52-week high of $11.45 (10 Sep 2026) and 122.0% above the low of $4.50 (30 Mar 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+14.0%

6 months+19.2%

1 year+31.3%

5 years—

Newswire

About

Website

Notable moves

April 27, 2026
+38.57%
June 12, 2025
+39.10%
January 22, 2024
+170.09%

Newswire

About

Website

Notable moves

April 27, 2026
+38.57%
June 12, 2025
+39.10%
January 22, 2024
+170.09%

Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc. in brief

8.2 days to cover short interest

Ahead of SPY, in line with its sector fund XLV over 1 year

Above its 50- and 200-day averages

79% of the way up its 52-week range

Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc. in brief

8.2 days to cover short interest

Ahead of SPY, in line with its sector fund XLV over 1 year

Above its 50- and 200-day averages

79% of the way up its 52-week range